Belzutifan's Role in Active Surveillance Versus Treatment for Indolentmetastatic Clear Cell Renal Ccell Carcinoma (BRAVE-RCC)

Recruiting

Phase 2

BelzutifanBelzutifan's Role in Active Surveillance Versus Treatment for Indolentmetastatic Clear Cell Renal Ccell Carcinoma (BRAVE-RCC)

Sponsor:

M.D. Anderson Cancer Center

Code:

NCT07023432

Conditions

Active Surveillance

Clear Cell Renal Cell Carcinoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Belzutifan

Active Surveillance

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-05-29. This information was provided to ClinicalTrials.gov by M.D. Anderson Cancer Center on 2026-05-22.